Other compounds in the plant appear to play a critical role.
For generations, cannabis occupied a strange liminal space in science—too legally fraught to study, too culturally charged to evaluate clearly. Now, as restrictions ease, researchers at UC Riverside have begun to illuminate a genuine paradox: cannabis users tend to weigh less and face lower diabetes risk, even though THC famously stimulates appetite. Mouse studies suggest the answer lies not in THC itself, but in the plant's vast, largely unexplored chemical complexity—a reminder that nature rarely yields its secrets to simple explanations.
- Obese mice fed a Western diet lost weight and body fat when treated with cannabis compounds, even while eating roughly the same amount as untreated mice who kept gaining—a result that defies the drug's reputation as an appetite trigger.
- The critical tension emerged when THC alone failed to replicate the metabolic benefits: only the full-plant extract improved glucose tolerance, forcing researchers to look beyond the plant's most famous molecule.
- Lesser-known compounds like CBG are now drawing serious attention, with early data suggesting they can improve blood sugar control and reduce liver fat through pathways that may not even involve classical cannabinoid receptors.
- Scientists are urging caution on all fronts—clinical evidence for human use remains absent, early-life THC exposure may carry developmental risks, and the field is moving fast enough that findings are outpacing the frameworks needed to interpret them.
- Cannabis research is accelerating at a historic pace, with publications increasing 4.5-fold since 2000, signaling that the next decade may redefine how medicine understands this plant's relationship to metabolic health.
For decades, legal and social restrictions kept cannabis science in the shadows. As regulations have loosened, researchers are finally testing what users and traditional medicine long suggested: that this plant might meaningfully affect metabolic health.
The puzzle begins with an epidemiological contradiction. Cannabis users tend to weigh less and face lower rates of type 2 diabetes than non-users—despite THC's well-known ability to trigger intense hunger. Researchers at UC Riverside decided to chase this paradox in the lab. They placed obese adult mice on a high-fat, high-sugar Western diet, then treated some with either pure THC or a full-plant cannabis extract containing equivalent THC levels. Both treated groups lost weight and body fat relative to untreated mice, even with similar food intake.
But the more revealing finding came from glucose metabolism. Only mice receiving the whole-plant extract showed improved ability to process blood sugar. Mice given THC alone showed no such benefit—pointing clearly toward other plant compounds as the drivers of metabolic change.
Biomedical scientist Nicholas DiPatrizio, who directs UCR's Center for Cannabinoid Research, noted that THC and appetite may operate on entirely different pathways than whatever governs glucose metabolism. The cannabis plant contains hundreds of active molecules—cannabinoids, terpenes, flavonoids—most of them poorly studied. One compound drawing new attention is CBG, which in recent mouse studies improved blood sugar control and reduced liver fat, apparently through mechanisms that bypass classical cannabinoid receptors entirely.
DiPatrizio was careful to temper enthusiasm. No clinical evidence currently supports using cannabis to manage weight or diabetes. Early-life THC exposure may disrupt fat storage in harmful ways, and rodent pups exposed to THC show reduced birth weights. The field is young, and not every finding will favor the plant.
The real work ahead involves identifying which compounds matter, how they interact, and whether mouse results translate to humans. Different cannabis strains carry different chemical profiles, and studying molecules in isolation may miss the larger picture. For now, the research has opened a door—what lies beyond it remains to be discovered.
For decades, cannabis research languished under legal and social restrictions. But as regulations have loosened across much of the world, including the United States, scientists are finally testing what users and traditional medicine have long suggested: that this plant might actually help with metabolic health.
The puzzle is real. Epidemiologists have noticed that people who use cannabis tend to weigh less and face lower risk of type 2 diabetes than non-users. This shouldn't make sense. THC, the main psychoactive compound in cannabis, is famous for triggering the munchies—that intense, almost irresistible hunger that sends users to the kitchen at odd hours. Yet somehow, cannabis users don't gain weight the way the drug's appetite-stimulating properties would predict.
Researchers at the University of California, Riverside decided to chase this contradiction in the lab. They took obese adult mice and fed them a Western diet—high in fat and sugar—for two months. Thirty days into this regimen, they began treating some mice with either pure THC or a full-plant cannabis extract containing the same amount of THC. The results were striking. Both groups of treated mice lost weight as the cannabis exposure continued, while untreated mice kept gaining. The treated animals also ended up with less body fat than their untreated counterparts, even though they ate roughly the same amount of food.
But here's where the story gets interesting. Only the mice receiving the whole-plant extract showed meaningful improvements in glucose tolerance—the ability to process blood sugar efficiently. The mice given THC alone showed no such metabolic shift. This finding upended a simple explanation. If THC were responsible for the benefits, both groups should have improved. Instead, the data pointed elsewhere: other compounds in the cannabis plant, not THC, appear to drive the metabolic gains.
Nicholas DiPatrizio, a biomedical scientist who directs the UCR Center for Cannabinoid Research, framed the implication carefully. THC might make you hungry, he explained, but other plant compounds seem to work on glucose metabolism through entirely different pathways. The cannabis plant contains hundreds of active molecules—cannabinoids, terpenes, flavonoids, and other phytochemicals—most of which remain poorly understood. Researchers have focused almost exclusively on THC and CBD, the two most famous compounds. But others, like CBG (cannabigerol), are showing real promise. Recent studies in obese mice suggest CBG can improve blood sugar control, reduce liver fat, and lower blood lipid levels, apparently through mechanisms that bypass the classical cannabinoid receptors altogether. There may be biological pathways we haven't even discovered yet.
DiPatrizio was careful not to oversell the findings. He explicitly cautioned against using cannabis to manage weight or diabetes—the clinical evidence simply doesn't exist. But he urged clinicians, researchers, and policymakers to watch this space closely. Cannabis research has accelerated dramatically in recent years. From 2000 to 2017, publications on cannabis in PubMed increased 4.5-fold, while medical cannabis publications nearly tripled. Thousands of new studies appear every year.
There are cautions embedded in the emerging data. Early-life exposure to THC, for instance, may disrupt the body's natural fat storage in ways that could be harmful. Rodent pups exposed to THC show reduced birth weights. The field is young, and not all findings will be positive. DiPatrizio emphasized the need for evidence-based approaches that illuminate both risks and potential benefits.
The real work ahead involves teasing apart which compounds matter, how they interact, and whether the effects seen in mice translate to humans. Different cannabis strains have different chemical compositions, which could produce different metabolic outcomes. The plant's complexity—hundreds of compounds, many of them interactive—means that studying individual molecules in isolation may miss the whole picture. For now, the mouse studies have opened a door. What lies beyond it remains to be discovered.
Notable Quotes
This suggests that THC alone is not responsible for the metabolic benefits associated with cannabis use. Other compounds in the plant appear to play a critical role.— Nicholas DiPatrizio, biomedical scientist and director of the UCR Center for Cannabinoid Research
Clinicians, researchers, and policymakers should stay tuned and pay attention to this space. We need evidence-based approaches to fully understand both the risks and potential benefits of cannabis and its components.— Nicholas DiPatrizio
The Hearth Conversation Another angle on the story
Why would cannabis users weigh less if THC makes them hungry? That seems backwards.
It does seem backwards, which is exactly why researchers got curious. The appetite stimulation is real, but somehow it's not translating to weight gain in actual users. The mouse study suggests the answer might be that other compounds in the plant are doing something metabolic that counteracts the hunger effect.
So THC alone isn't the answer?
Not according to this work. When they gave mice pure THC, the mice lost weight but didn't show the glucose improvements. Only the full-plant extract did that. It's like THC is one piece of a much larger puzzle.
What are these other compounds?
That's the frontier. The plant has hundreds of them. Most research has focused on just THC and CBD, but compounds like CBG are starting to show real metabolic effects in animal studies. The problem is we've barely scratched the surface of understanding how they work or how they interact with each other.
Is this ready for people to use as medicine?
Not yet. DiPatrizio was explicit about that. There's no clinical evidence in humans. These are mouse studies. But he's saying the field is moving fast enough that doctors and policymakers should pay attention to what's coming next.
What could go wrong?
Early exposure to THC in developing animals shows concerning effects—reduced birth weights, for instance. We don't know yet if those translate to humans or what the long-term consequences might be. That's why he emphasized the need for evidence-based approaches that look at both benefits and risks.